Skip to search formSkip to main contentSkip to account menu

ametantrone

Known as: 9, 10-Anthracenedione, 1, 4-bis[[2-[(2-hydroxyethyl)amino]ethyl]amino]-, HAQ, 1,4-bis[[2-[(2-Hydroxyethyl)amino]ethyl]amino]9,10-anthracenedione 
A topoisomerase II inhibitor of the anthrapyrazole family that causes covalent cross-links in DNA of tumor cells.
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Background: Treatment strategy after achieving sustained remission in rheumatic conditions remains uncertain. Objetives: to… 
2015
2015
Objective: To compare the effect of comprehensive rehabilitation program versus combined garlic therapy and comprehensive… 
2014
2014
Objectives: This study aims to investigate the relationship of hemoglobin level with disease activity in patients with rheumatoid… 
2013
2013
Background: It was thought that women report higher pain than men. We studied if there was a sex difference for several patient… 
2012
2012
La discapacidad laboral ocurre de forma temprana en pacientes con Artritis Reumatoidea (AR), con un importante impacto… 
2002
2002
SUMMARY The level of activity was assessed in 334 out-patients who visited the Clinic of Physical Medicine at the… 
1996
1996
tests. The MHAQ total scores were on average 31-5% lower than those of the full HAQ (1-49 (SD 074) for the HAQ and 1-02 (1-00… 
1985
1985
The anthracenedione antineoplastic agents mitoxantrone and ametantrone are potent inhibitors of basal and drug-stimulated lipid… 
1983
1983
Ametantrone is the third of a family of anthracene derivatives to undergo a phase I trial in man. Sixteen patients received 33… 
1980
1980
1,4-Bis (2-[(2-hydroxyethyl)amino]ethylamino)-9,10-anthracenedione (NSC 287513) (HAQ) may be selected for clinical trial based on…